|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2004-4-7
|
|
pubmed:abstractText |
To investigate the influence of autologous cytokine-induced killer (CIK) cells on the phenotypes of CIK effector cells, peripheral T lymphocyte subsets and dendritic cell subsets in patients with primary hepatocellular carcinoma (HCC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1007-9327
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1146-51
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:15069715-Adoptive Transfer,
pubmed-meshheading:15069715-Adult,
pubmed-meshheading:15069715-Antibodies, Monoclonal,
pubmed-meshheading:15069715-Antigens, CD3,
pubmed-meshheading:15069715-Antineoplastic Agents,
pubmed-meshheading:15069715-Carcinoma, Hepatocellular,
pubmed-meshheading:15069715-Female,
pubmed-meshheading:15069715-Hepatitis B, Chronic,
pubmed-meshheading:15069715-Humans,
pubmed-meshheading:15069715-Immunophenotyping,
pubmed-meshheading:15069715-Interferon-gamma,
pubmed-meshheading:15069715-Interleukin-2,
pubmed-meshheading:15069715-Killer Cells, Natural,
pubmed-meshheading:15069715-Liver Neoplasms,
pubmed-meshheading:15069715-Male,
pubmed-meshheading:15069715-Middle Aged,
pubmed-meshheading:15069715-T-Lymphocyte Subsets,
pubmed-meshheading:15069715-Viral Load
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma.
|
|
pubmed:affiliation |
Research Center of Biotherapy, Beijing Institute of Infectious Diseases, 302 Hospital of PLA, Beijing 100039, China.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
